Table I.
Clinical and pathological characteristics of patients in the study
| Parameter | MIVAP (n = 151) | OMIP (n = 304) | Value of p |
|---|---|---|---|
| Gender, n (%): | 0.075 | ||
| Female | 138 (91.4) | 260 (85.5) | |
| Male | 13 (8.6) | 44 (14.5) | |
| Age, mean ± SD (range) [years] | 51.7 ±14.9 (18–75) | 57.7 ±16.3 (18–82) | < 0.001 |
| BMI, mean ± SD (range) [kg/m2] | 27.2 ±4.5 (19.2–35.0) | 27.3 ±4.8 (19.4–35.7) | 0.838 |
| Total serum calcium level, mean ± SD (range) [mmol/l] | 2.95 ±0.16 (2.69–3.21) | 3.02 ±0.19 (2.69–3.65) | < 0.001 |
| iPTH serum level, mean ± SD (range) [ng/l] | 257.5 ±97.2 (101.1–421.5) | 280.0 ±105.7 (110.2–860.4) | 0.028 |
| Creatinine, mean ± SD (range) [µmol/l] | 86.1 ±15.7 (65–116) | 87.9 ±15.0 (63–117) | 0.238 |
| Alkaline phosphatase, mean ± SD (range) [IU/l] | 130.5 ±27.0 (37–230) | 140.3 ±36.7 (39–239) | 0.231 |
| Pathology, n (%): | 0.709 | ||
| Single parathyroid adenoma | 147 (97.3) | 294 (96.7) | |
| Double parathyroid adenoma | 3 (2.0) | 9 (3.0) | |
| Four-gland parathyroid hyperplasia | 1 (0.7) | 1 (0.3) | |
| Parathyroid cancer | 0 (0.0) | 0 (0.0) | |
| Adenoma weight, mean ± SD (range) [g] | 1.97 ±1.46 (0.25–4.68) | 2.30 ±1.65 (0.48–5.69) | < 0.001 |
| Localization of the parathyroid adenoma, n (%): | 0.737 | ||
| Right superior | 35 (23.3) | 74 (24.4) | |
| Right inferior | 40 (26.7) | 82 (27.1) | |
| Left superior | 37 (24.7) | 74 (24.4) | |
| Left inferior | 41 (27.3) | 82 (27.1) | |
| Disease, n (%): | 0.089 | ||
| Symptomatic | 104 (68.9) | 232 (76.3) | |
| Asymptomatic | 47 (31.1) | 72 (23.7) |
BMI – body mass index, iPTH – intact parathyroid hormone. Reference ranges: total calcium (2.2–2.6 mmol/l), iPTH (12–65 ng/l), creatinine (60–120 µmol/l), total alkaline phosphatase (30–260 IU/l)